NEW YORK (GenomeWeb News) – GeneNews today announced the approval of almost MYR1.9 million ($608,000) in a seed capital grant from the Malaysian Biotechnology Corporation to support the commercial launch of the ColonSentry colorectal cancer diagnostic test in Malaysia.
The test will be made available in Malaysia through GeneNews Diagnostics, a privately held Malaysian firm that will also work with GeneNews to introduce ColonSentry in the rest of Southeast Asia.
In a statement, Galina Liew, president and COO of GeneNews, said that commercialization and clinical adoption of the test is the company's primary goal and the grant will "help to address critical funding needs to accelerate the launch of ColonSentry in Malaysia," which she called a key country in Southeast Asia.
The test was initially launched in 2008 in Canada. The company added that with its marketing partner in China, Gene Diagnostics, it anticipates launching the test there in the fourth quarter. It and Enzo Clinical Labs will launch the test in the US during the first half of 2011.